PET imaging of cardiac hypoxia: Opportunities and challenges

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 5, 2011, Pages 640-650

  Handley, M G ^a   Medina, R A ^a   Nagel, E ^a   Blower, P J ^a   Southworth, R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

18FMISO; 64Cu ATSM; Copper bis(thiosemicarbazones); Fluoromisonidazole; Hypoxia; Positron Emission Tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; COPPER 2,3 BUTANEDIONE BIS(N4 METHYLTHIOSEMICARBAZONE); COPPER 2,3 BUTANEDIONE BIS(THIOSEMICARBAZONE); COPPER 2,3 PENTANEDIONE BIS(THIOSEMICARBAZONE); COPPER 3,4 HEXANEDIONE BIS(N4 METHYLTHIOSEMICARBAZONE); COPPER 3,4 HEXANEDIONE BIS(THIOSEMICARBAZONE); COPPER DIACETYL BIS(N4 ETHYLTHIOSEMICARBAZONE); COPPER PYRUVALDEHYDE BIS(N4 METHYLTHIOSEMICARBAZONE); FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MISONIDAZOLE; OXYGEN; THALLIUM 201; THIOSEMICARBAZIDE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ACIDOSIS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG SCREENING; DRUG STRUCTURE; DRUG UPTAKE; GOLD STANDARD; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; INTERMETHOD COMPARISON; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW;

ACIDOSIS; ANIMALS; ANOXIA; COPPER; COPPER RADIOISOTOPES; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; HUMANS; MISONIDAZOLE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIATION-SENSITIZING AGENTS; RATS; REDUCING AGENTS; SENSITIVITY AND SPECIFICITY; THIOSEMICARBAZONES; TISSUE DISTRIBUTION;

EID: 80053247686     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.07.005     Document Type: Review

References (118)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
2. Fraser A.G., Buser P.T., Bax J.J., Dassen W.R., Nihoyannopoulos P., Schwitter J., et al. The future of cardiovascular imaging and non-invasive diagnosis. Eur Heart J 2006, 27:1750-1753.
3. Chen I.Y., Wu J.C. Cardiovascular molecular imaging: focus on clinical translation. Circulation 2011, 123:425-443.
4. Sinusas A.J. The potential of myocardial imaging with hypoxia markers. Semin Nucl Med 1999, 29:330-338.
5. Hearse D.J. Myocardial ischaemia: can we agree on a definition for the 21st century?. Cardiovasc Res 1994, 28:1737-1744.
6. de Boer R.A., Pinto Y.M., van Veldhuisen D.J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003, 10:113-126.
7. Nagel E., Klein C., Paetsch I., Hettwer S., Schnackenburg B., Wegscheider K., et al. Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease. Circulation 2003, 108:432-437.
8. Hachamovitch R., Hayes S.W., Friedman J.D., Cohen I., Berman D.S. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003, 107:2900-2907.
9. Rahimtoola S.H. A perspective on the three large multicenter randomised clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985, 72:V123-V135.
10. Heusch G., Schulz R., Rahimtoola S.H. Myocardial hibernation: a delicate balance. Am J Physiol 2005, 288:H984-H999.
11. Camici P.G., Rimoldi O. Myocardial hibernation vs. repetitive stunning in patients. Cardiol Rev 1999, 7:39-43.
12. Feldhaus L.M., Liedtke A.J. mRNA expression of glycolytic enzymes and glucose transporter proteins in ischemic myocardium with and without reperfusion. J Mol Cell Cardiol 1998, 30:2475-2485.
13. Depre C., Vanoverschelde J.L., Melin J.A., Borgers M., Bol A., Ausma J., et al. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol 1995, 268:H1265-H1275.
14. Michelena H.I., Vecker W.A. Radionuclide-based insights into the pathophysiology of ischemic heart disease: beyond diagnosis. J Investig Med 2005, 53:176-191. 10.2310/6650.2005.00401.
15. Uren N.G., Camici P.G. Hibernation and myocardial ischemia: clinical detection by positron emission tomography. Cardiovasc Drugs Ther 1992, 6:273-279.
16. Camici P.G., Prasad S.K., Rimoldi O.E. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008, 117:103-114.
17. Southworth R. Hexokinase-mitochondrial interaction in cardiac tissue: implications for cardiac glucose uptake, the 18FDG lumped constant and cardiac protection. J Bioenerg Biomembr 2009, 41:187-193.
18. Garlick P.B., Medina R.A., Southworth R., Marsden P.K. Differential uptake of FDG and DG during post-ischaemic reperfusion in the isolated, perfused rat heart. Eur J Nucl Med 1999, 26:1353-1358.
19. Southworth R., Dearling J.L., Medina R.A., Flynn A.A., Pedley R.B., Garlick P.B. Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischaemic isolated rat heart: application of a new autoradiographic technique. Eur J Nucl Med Mol Imaging 2002, 29:1334-1341.
20. Hariharan R., Bray M., Ganim R., Doenst T., Goodwin G.W., Taegtmeyer H. Fundamental limitations of [18F]2-deoxy-2-fluoro-d-glucose for assessing myocardial glucose uptake. Circulation 1995, 91:2435-2444.
21. Doenst T., Taegtmeyer H. Profound underestimation of glucose uptake by [18F]2-deoxy-2-fluoroglucose in reperfused rat heart muscle. Circulation 1998, 97:2454-2462.
22. Barrington S.F., Chambers J., Hallett W.A., O'Doherty M.J., Roxburgh J.C., Nunan T.O. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging 2004, 31:355-361.
23. Piwnica-Worms D., Kronauge J.F., LeFurgey A., Backus M., Hockett D., Ingram P., et al. Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe x-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging 1994, 12:641-652.
24. Schwaiger M., Muzik O. Assessment of myocardial perfusion by positron emission tomography. Am J Cardiol 1991, 67:35D-43D.
25. Depre C., Vatner S.F. Mechanisms of cell survival in myocardial hibernation. Trends Cardiovasc Med 2005, 15:101-110.
26. Bonow R.O., Udelson J.E. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med 1992, 117:502-510.
27. Hoenig MB C., Rosenswieg A., Sellke F.W. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol 2008, 6:292-300.
28. Des Tombe A.L., Van Beek-Harmsen B.J., Lee-De Groot M.B.E., Van Der Laarse W.J. Calibrated histochemistry applied to oxygen supply and demand in hypertrophied rat myocardium. Microsc Res Tech 2002, 58:412-420.
29. Shyu KGL J.Y., Wang B.W., Fang W.J., Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1a and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci 2005, 12:409-420.
30. Krishnan J., Suter M., Windak R., Krebs T., Felley A., Montessuit C., et al. Activation of a HIF1[alpha]-PPAR[gamma] axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009, 9:512-524.
31. El Jamali A., Freund C., Rechner C., Scheidereit C., Dietz R., Bergmann M.W. Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3β. FASEB J 2004, 18(10):1096-1098.
32. Anversa P., Capasso J.M. Loss of intermediate-sized coronary arteries and capillary proliferation after left ventricular failure in rats. Am J Physiol 1991, 260:H1552-H1560.
33. Biolo A., Greferath R., Siwik D.A., Qin F., Valsky E., Fylaktakidou K.C., et al. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. PNAS 2009, 106:1926-1929.
34. Bekeredjian R., Walton C.B., MacCannell K.A., Ecker J., Kruse F., Outten J.T., et al. Conditional HIF-1α expression produces a reversible cardiomyopathy. PLoS One 2010, 5:e11693.
35. Dobrucki LWM D.F., Hu J., Sadeghi M.M., Sinusas A.J. Regional hypoxia correlates with the uptake of a radiolabelled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury. J Physiol Pharmacol 2009, 60:117-123.
36. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med Mol Imaging 1995, 22:265-280.
37. Chung Y. Oxygen reperfusion is limited in the postischemic hypertrophic myocardium. Am J Physiol 2006, 290:H2075-H2084.
38. Williamson J.R., Kobayashi K. Use of the perfused rat heart to study cardiac metabolism: retrospective and prospective views. Basic Res Cardiol 1984, 79:283-291.
39. Zhang J., Ugurbil K., From A.H.L., Bache R.J. Myocardial oxygenation and high-energy phosphate levels during graded coronary hypoperfusion. Am J Physiol 2001, 280:H318-H326.
40. Kreutzer U., Mekhamer Y., Chung Y., Jue T. Oxygen supply and oxidative phosphorylation limitation in rat myocardium in situ. Am J Physiol 2001, 280:H2030-H2037.
41. Mik E.G., Ince C., Eerbeek O., Heinen A., Stap J., Hooibrink B., et al. Mitochondrial oxygen tension within the heart. J Mol Cell Cardiol 2009, 46:943-951.
42. Nesto R.W., Kowalchuk G.J. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol 1987, 59:C23-C30.
43. Camici P.G., Rimoldi O.E. The clinical value of myocardial blood flow measurement. J Nucl Med 2009, 50:1076-1087.
44. Jerosch-Herold M. Quantification of myocardial perfusion by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010, 12:57.
45. Lowe J., Cummings R., Adams D., Hull-Ryde E. Evidence that ischemic cell death begins in the subendocardium independent of variations in collateral flow or wall tension. Circulation 1983, 68:190-202.
46. Jameel M.N., Wang X., Eijgelshoven M.H.J., Mansoor A., Zhang J. Transmural distribution of metabolic abnormalities and glycolytic activity during dobutamine-induced demand ischemia. Am J Physiol 2008, 294:H2680-H2686.
47. Fujiwara H., Ashraf M., Sato S., Millard R. Transmural cellular damage and blood flow distribution in early ischemia in pig hearts. Circ Res 1982, 51:683-693.
48. Garlick P.B., Radda G.K., Seeley P.J., Chance B. Phosphorus NMR studies on perfused heart. Biochem Biophys Res Commun 1977, 74:1256-1262.
49. Hardy C.J., Weiss R.G., Bottomley P.A., Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991, 122:795-801.
50. Neubauer S., Krahe T., Schindler R., Horn M., Hillenbrand H., Entzeroth C., et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992, 86:1810-1818.
51. Hansch A., Rzanny R., Heyne J.P., Leder U., Reichenbach J.R., Kaiser W.A. Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging. Eur Radiol 2005, 15:319-323.
52. Neubauer S., Horn M., Cramer M., Harre K., Newell J.B., Peters W., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190-2196.
53. Holloway C., Cochlin L., Codreanu I., Bloch E., Fatemian M., Szmigielski C., et al. Normobaric hypoxia impairs human cardiac energetics. FASEB J 2011, 25(2):792-796.
54. Garlick P.B., Marsden P.K., Cave A.C., Parkes H.G., Slates R., Shao Y., Silverman R.W., Cherry S.R.P.E.T. NMR dual acquisition (PANDA): applications to isolated, perfused rat hearts. NMR Biomed 1997, 10:138-142.
55. Hoffend J., Linke G., Mohammed A., Tiefenbacher C.P., Eisenhut M., Haberkorn U. 99mTcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium. Eur J Nucl Med Mol Imaging 2003, 30:494-501.
56. Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol.2:437-45.
57. Krohn K.A., Link J.M., Mason R.P. Molecular imaging of hypoxia. J Nucl Med 2008, 49:129S-148S.
58. Whitmore G.F., Varghese A.J. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem Pharmacol 1986, 35:97-103.
59. Kedderis G.L., Miwa G.T. The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab Rev 1988, 19:33-62.
60. Martin G., Cerqueira M., Caldwell J., Rasey J., Embree L., Krohn K. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res 1990, 67:240-244.
61. Martin G.V., Caldwell J.H., Graham M.M., Grierson J.R., Kroll K., Cowan M.J., et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 1992, 33:2202-2208.
62. Martin G.V., Biskupiak J.E., Caldwell J.H., Rasey J.S., Krohn K.A. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med 1993, 34:918-924.
63. Shelton M.E., Dence C.S., Hwang D.-R., Welch M.J., Bergmann S.R. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med 1989, 30:351-358.
64. Shelton M.E., Dence C.S., Hwang D.-R., Herrero P., Welch M.J., Bergmann S.R. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990, 16:477-485.
65. Martin G.V., Caldwell J.H., Rasey J.S., Grunbaum Z., Cerqueira M., Krohn K.A. Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989, 30:194-201.
66. Strauss H.W., Nunn A., Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 1995, 2:437-445.
67. Blower P.J., Lewis J.S., Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996, 23:957-980.
68. Green M.A. A potential copper radiopharmaceutical for imaging the heart and brain: copper-labeled pyruvaldehyde bis(N4-methylthiosemicarbazone). Int J Rad Appl Instrum B 1987, 14:59-61.
69. Green M.A., Klippenstein D.L., Tennison J.R. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J Nucl Med 1988, 29:1549-1557.
70. Shelton M.E., Green M.A., Mathias C.J., Welch M.J., Bergmann S.R. Kinetics of copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. J Nucl Med 1989, 30:1843-1847.
71. Shelton M.E., Green M.A., Mathias C.J., Welch M.J., Bergmann S.R. Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography. Circulation 1990, 82:990-997.
72. Dearling J.L.J., Lewis J.S., Mullen G.E.D., Rae M.T., Zweit J., Blower P.J. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med Mol Imaging 1998, 25:788-792.
73. McQuade P., Martin K.E., Castle T.C., Went M.J., Blower P.J., Welch M.J., et al. Investigation into 64Cu-labeled bis(selenosemicarbazone) and bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol 2005, 32:147-156.
74. Zhu X., Zuo L., Cardounel A.J., Zweier J.L., He G. Characterization of in vivo tissue redox status, oxygenation, and formation of reactive oxygen species in postischemic myocardium. Antioxid Redox Signal 2007, 9:447-455.
75. Katz A., Edlund A., Sahlin K. NADH content and lactate production in the perfused rabbit heart. Acta Physiol Scand 1987, 130:193-200.
76. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129.
77. LJ Dearling J., J Blower P. Redox-active metal complexes for imaging hypoxic tissues: structure-activity relationships in copper(II) bis(thiosemicarbazone) complexes. Chem Commun 1998, 2531-2532.
78. Blower P.J., Castle T.C., Cowley A.R., Dilworth J.R., Donnelly P.S., Labisbal E., et al. Structural trends in copper(ii) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans 2003, 4416-4425.
79. Castle T.C., Maurer R.I., Sowrey F.E., Went M.J., Reynolds C.A., McInnes E.J.L., et al. Hypoxia-targeting copper bis(selenosemicarbazone) complexes: comparison with their sulfur analogues. J Am Chem Soc 2003, 125:10040-10049.
80. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002, 7:249-259.
81. Wada K., Fujibayashi Y., Tajima N., Yokoyama A. Cu-ATSM, an intracellular-accessible superoxide dismutase (SOD)-like copper complex: evaluation in an ischemia-reperfusion injury model. Biol Pharm Bull 1994, 17:701-704.
82. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997, 38:1155-1160.
83. Dehdashti F., Mintun M.A., Lewis J.S., Bradley J., Govindan R., Laforest R., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
84. Takahashi N., Fujibayashi Y., Yonekura Y., Welch M.J., Waki A., Tsuchida T., et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000, 14:323-328.
85. Dehdashti F., Grigsby P.W., Lewis J.S., Laforest R., Siegel B.A., Welch M.J. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
86. Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., Welch M.J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55:1233-1238.
87. Lewis J.S., Laforest R., Dehdashti F., Grigsby P.W., Welch M.J., Siegel B.A. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008, 49:1177-1182.
88. Dietz D.W., Dehdashti F., Grigsby P.W., Malyapa R.S., Myerson R.J., Picus J., et al. Tumor hypoxia detected by positron emission tomography with (60)Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51(11):1641-1648.
89. Lewis J.S., Herrero P., Sharp T.L., Engelbach J.A., Fujibayashi Y., Laforest R., et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J Nucl Med 2002, 43:1557-1569.
90. Takahashi N., Fujibayashi Y., Yonekura Y., Welch M.J., Waki A., Tsuchida T., et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med 2001, 15:293-296.
91. Dearling J.L., Lewis J.S., Mullen G.E., Rae M.T., Zweit J., Blower P.J. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998, 25:788-792.
92. Lewis J.S., McCarthy D.W., McCarthy T.J., Fujibayashi Y., Welch M.J. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40:177-183.
93. Bjerrum J.T., Perko M.J., Beck B. Myocardial oxygen tension during surgical revascularization: a clinical comparison between blood cardioplegia and crystalloid cardioplegia. Eur J Cardiothorac Surg 2006, 29:181-185.
94. Barrett J.A., Lynch V.D., Balkon J., Wolf P.S. Measurement of oxygen tension in the ischemic myocardium using encased polargraphic oxygen electrodes. J Pharmcol Meth 1986, 15:235-243.
95. Shibano T., Abiko Y. Effects of nitroglycerin, dipyridamole and propranolol on myocardial pH and pO2 during regional ischemia in the dog heart. Arch Int Pharmacodyn Ther 1983, 264:274-289.
96. Dearling JLJ, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol.37:237-43.
97. Wood K.A., Honess D.J., Maxwell R.J., Wilson J., Paul R.L., O'Doherty M.J., et al. Evaluation of the effects of blood flow on 64Cu-ATSM uptake in a rodent tumour model. Clin Oncol 2007, 19:S35-S36.
98. Fujibayashi Y., Cutler C.S., Anderson C.J., McCarthy D.W., Jones L.A., Sharp T., et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 1999, 26:117-121.
99. Lewis J.S., Herrero P., Sharp T.L., Engelbach J.A., Fujibayashi Y., Laforest R., et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2002, 43:1557-1569.
100. Fujibayashi Y., Taniuchi H., Wada K., Yonekura Y., Konishi J., Yokoyama A. Differential mechanism of retention of Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: a novel radiopharmaceutical for positron emission tomography imaging. Ann Nucl Med 1995, 9:1-5.
101. Obata A., Yoshimi E., Waki A., Lewis J.S., Oyama N., Welch M.J., et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001, 15:499-504.
102. Shibuya KF Y., Yoshimi E., Sasai K., Hiraoka M., Welch M.J. Cytosolic/microsomal redox pathway: a reductive retention mechanism of a PET-oncology tracer, Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (PTSM). Ann Nucl Med 1999, 13:287-292.
103. Fujibayashi Y., Wada K., Taniuchi H., Yonekura Y., Konishi J., Yokoyama A. Mitochondria-selective reduction of 62Cu-pyruvaldehyde bis(N4-methylthiosemicarbazone) (62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol Pharm Bull 1993, 16:146-149.
104. Obata A., Yoshimi E., Waki A., Lewis J.S., Oyama N., Welch M.J., et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001, 15:499-504.
105. Shibuya K., Fujibayashi Y., Yoshimi E., Sasai K., Hiraoka M., Welch M.J. Cytosolic/microsomal redox pathway: a reductive retention mechanism of a PET-oncology tracer, cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (cu-PTSM). Ann Nucl Med 1999, 13:287-292.
106. Baerga I.D., Maickel R.P., Green M.A. Subcellular distribution of tissue radiocopper following intravenous administration of 67Cu-labeled Cu-PTSM. Int J Radiol Appl Instrum B Nucl Med Biol 1992, 19:697-701.
107. Burgman P., O'Donoghue J.A., Lewis J.S., Welch M.J., Humm J.L., Ling C.C. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005, 32:623-630.
108. Warren L.E., Horner S.M., Hatfield W.E. Chemistry of.alpha.-diketone-bis(thiosemicarbazone)copper(II) complexes. J Am Chem Soc 1972, 94:6392-6396.
109. Minkel D.T., Petering D.H. Initial reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II) with ehrlich ascites tumor cells. Cancer Res 1978, 38:117-123.
110. Petering D.H. Physico-chemical properties of the antitumor agent, 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II). Bioinorg Chem 1972, 1:225-271.
111. Taniuchi H., Fujibayashi Y., Okazawa H., Yonekura Y., Konishi J., Yokoyama A. Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: a potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET). Biol Pharm Bull 1995, 18:1126-1129.
112. John E.K., Green M.A. Structure-activity relationships for metal-labeled blood flow tracers: comparison of keto aldehyde bis(thiosemicarbazonato)copper(II) derivatives. J Med Chem 1990, 33:1764-1770.
113. Petering D.H. The reaction of 3-ethoxy-2-oxobutyraldehyde bis (thiosemicarbazonato) copper(II) with thiols. Bioinorg Chem 1972, 1:273-288.
114. Barnhart A.J., Voorhees W.D., Green M.A. Correlation of Cu(PTSM) localization with regional blood flow in the heart and kidney. Int J Radiol Appl Instrum: B Nucl Med Biol 1989, 16:747-748.
115. Maurer R.I., Blower P.J., Dilworth J.R., Reynolds C.A., Zheng Y., Mullen G.E., et al. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 2002, 45:1420-1431.
116. Holland J.P., Green J.C., Dilworth J.R., Holland J.P., Green J.C., Dilworth J.R. Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans 2006, 783-794.
117. Holland J.P., et al. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol 2009, 54:2103.
118. Blower P.J., Went M.J., Martin K.E., Smith G.E. Imaging hypoxia in vivo by controlling the electrochemistry of copper radionuclide complexes. J Labelled Comp Radiopharm 2007, 50:354-359.